目的 探讨乙酰半胱氨酸联合头孢唑肟治疗新生儿肺炎的临床疗效。方法 选择2019年4月-2021年4月在南阳市中心医院治疗的96例新生儿肺炎患者,依据用药不同分成对照组和治疗组,每组各48例。对照组静脉滴注注射用头孢唑肟钠, 50 mg/kg加入15 mL生理盐水, 1次/8 h;治疗组在对照组基础上雾化吸入吸入用乙酰半胱氨酸溶液, 3 mL/次, 2次/d。两组均经10 d治疗。观察两组患儿临床疗效,比较治疗前后两组患儿临床症状改善时间,及血清炎症因子C反应蛋白(CRP)、降钙素原(PCT)和白细胞介素-6(IL-6)水平。结果 经治疗,对照组和治疗组有效率分别为83.33%、97.92%,两组比较差异有统计学意义(P<0.05)。经治疗,治疗组患儿临床症状改善时间均明显早于对照组(P<0.05)。经治疗,两组患儿血清炎症因子CRP、PCT和IL-6水平均明显下降(P<0.05),且治疗组患儿明显低于对照组(P<0.05)。结论 乙酰半胱氨酸联合头孢唑肟治疗新生儿肺炎可有效改善患儿临床症状,促进机体炎症因子水平下降,有利于患儿肺通气肺换气功能改善。

Objective To investigate the effects of acetylcysteine combined with cefazoxime in treatment of neonatal pneumonia.Methods Newborn (96 cases) with pneumonia in Nanyang Central Hospital from April 2019 to April 2021 were divided into control and treatment group based on different treatments, and each group had 48 cases. Newborn in the control group were iv administered with Ceftizoxime Sodium for injection, 50 mg/kg added into normal saline 15 mL, once every 8 h. Newborn in the treatment group were atomization inhalation administered with Acetylcysteine Solution for inhalation on the basis of the control group, 3 mL/time, twice daily. Newborn in two groups were treated for 10 d. After treatment, the clinical evaluation was evaluated, the improvement time of clinical symptoms, the levels of inflammatory mediators CRP, PCT and IL-6 in two groups before and after treatment were compared.Results After treatment, the effective rates of the control group and the treatment group were 83.33% and 97.92% respectively (P < 0.05). After treatment, the improvement time of clinical symptoms in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the serum inflammatory factors CRP, PCT and IL-6 in two groups were significantly decreased (P < 0.05), and which in the treatment group were significantly lower than those in the control group (P < 0.05).Conclusion Acetylcysteine combined with cefazoxime in treatment of neonatal pneumonia can effectively improve the clinical symptoms, reduce the level of inflammatory factors, and improve the pulmonary ventilation function.

R974;R985

河南省医学科技攻关计划联合项目(LHGJ20200649)